SCHEMBL27018128

SCHEMBL27018128

CC(C)(C)OC(=O)Oc1ccc(I)ccc1=O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 1/20 0.44
▸ BRD4 O60885 2/20 0.34
▸ KDM1A O60341 1/20 0.33
▸ GABRG2 P18507 2/20 0.32
▸ GABRB3 P28472 2/20 0.32
▸ GABRA5 P31644 2/20 0.32
▸ GABRA1 P14867 1/20 0.32
▸ GABRA3 P34903 1/20 0.32
▸ GABRA2 P47869 1/20 0.32
▸ MTNR1A P48039 2/20 0.32
▸ MTNR1B P49286 2/20 0.32
▸ MAPT P10636 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ CA2 P00918 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ TPMT P51580 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23258874 0.85 ELANE (0.45) ELANEBRD4KDM1AMTNR1AMTNR1B
SCHEMBL23258827 0.85 ELANE (0.45) ELANEBRD4KDM1AMTNR1AMTNR1B
SCHEMBL26965771 0.84 MAPT (0.38) MAPTKMT2ASMN1; SMN2CA2TPMT
SCHEMBL23258561 0.83 ELANE (0.44) ELANEBRD4KDM1AGABRG2GABRB3
SCHEMBL23249891 0.83 ELANE (0.44) ELANEBRD4KDM1AMTNR1AMTNR1B
SCHEMBL23258511 0.82 ELANE (0.50) ELANEKDM1AMTNR1AMTNR1BMAPT
SCHEMBL27018499 0.81 TYR (0.43) ELANEBRD4KDM1AMAPTKMT2A
SCHEMBL27259497 0.80 ELANE (0.44) ELANEBRD4KDM1AGABRG2GABRB3
SCHEMBL27018501 0.80 ELANE (0.47) ELANEBRD4KDM1AMTNR1AMTNR1B
SCHEMBL6391243 0.79 ELANE (0.68) ELANEKDM1AMAPTKMT2ACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 — — US disclosed
US-20230406803-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Kinesid Therapeutics, Inc (US) 2023-12-21 — — US disclosed
EP-4045025-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2022-08-24 — — EP disclosed
EP-4045477-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2022-08-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS TXNRD2, TXNRD1, SDHB ELANE 4033/4885BRD4 4625/4885KDM1A 3390/4885
US-20230406803-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS TXNRD2, TFRC, SDHB ELANE 4361/4885BRD4 4746/4885KDM1A 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback